# US 2006/0153854 A1 · Antibody induced cell membrane wounding

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0153854 A1
- Document ID: US20060153854A1
- Status: Published application
- Kind: A1
- Application number: 11/267,935
- Filed: 2005-11-04
- Published: 2006-07-13
- Earliest claimed: 2004-11-05
- Assignees: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Neelima Bhat; Marcia Bieber; Nelson Teng; Martin Sanders
- Web page: https://patentgrep.com/patent/US20060153854A1

## CPC

- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61K 31/475: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375)
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 38/50: acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/16: for decreasing, blocking or antagonising the activity of the thyroid hormones
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/06: Antianaemics
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions and methods for inducing cell membrane wounding, cell permeabilization and cell killing are provided. The composition comprises a polyvalent agent that binds to a highly expressed cell surface antigen present on the surface of a cell. Preferably, the cell surface antigen is associated with the cytoskeleton of the cell. A preferred polyvalent agent is an IgM, and enhanced cell wounding and killing can be provided by the addition of a crosslinking agent. At sublethal concentrations in vivo, the cell wounding antibodies permeabilize cells and dramatically enhance response to chemotherapeutic agents, even in patients refractory to the chemotherapeutic agents.

## Claims

### Claim 1

A composition for inducing cell membrane wounding, comprising a polyvalent agent that binds to a highly expressed cell surface antigen present on the surface of a cell, wherein said cell surface antigen is associated with the cytoskeleton of the cell.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the polyvalent agent is an antibody.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the antibody is an IgM.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the cell surface antigen is the CDIM epitope present on the surface of B cells.

### Claim 5 (depends on 1)

The composition of claim 1, further comprising a crosslinking agent providing crosslinking of the polyvalent agent that binds to the highly expressed cell surface antigen present on the surface of the cell.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the crosslinking agent is an antibody.

### Claim 7

A composition for augmenting cell membrane wounding in a lymphoid cell, comprising a polyvalent agent that binds to a highly expressed cell surface antigen on a lymphoid cell, and further comprising a crosslinking agent that augments the cell membrane wounding of the polyvalent agent relative to the cell membrane wounding of the polyvalent agent in the absence of the crosslinking agent.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the polyvalent agent is an antibody.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the antibody is an IgM.

### Claim 10 (depends on 7)

The composition of claim 7, wherein the cell surface antigen is the CDIM epitope present on the surface of B cells.

### Claim 11 (depends on 7)

The composition of claim 7, wherein the crosslinking agent is an antibody.

### Claim 12

A composition for killing a cell, comprising a polyvalent agent that binds to a highly expressed cell surface antigen present on the surface of a cell, and further comprising a crosslinking agent providing crosslinking of the polyvalent agent.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the polyvalent agent is a VH4-34 antibody.

### Claim 14 (depends on 12)

The composition of claim 12, wherein the crosslinking agent is an anti-kappa agent, anti-lambda agent, or an anti-VH4-34 antibody.

### Claim 15 (depends on 12)

The composition of claim 12, further comprising a cytotoxic agent.

### Claim 16 (depends on 12)

The composition of claim 12, wherein the cell is malignant.

### Claim 17 (depends on 16)

The composition of claim 16, wherein the malignant-cell is associated with a neoplasm of a body tissue selected from nerve, lymphoid, ovarian, cervical, endometrial, testicular, prostate, kidney, colon, pancreas, stomach, intestinal, esophagus, lung, thyroid, adrenal, liver, bone, skin, mouth, or throat.

### Claim 18

A composition for permeabilizing a cell, comprising a polyvalent agent that binds to a highly expressed cell surface antigen present on the surface of a cell.

### Claim 19 (depends on 18)

The composition of claim 18, wherein the cell is a B cell.

### Claim 20 (depends on 17)

The composition of claim 17, wherein the polyvalent agent is an antibody.

### Claim 21 (depends on 18)

The composition of claim 18, wherein the antibody is an IgM.

### Claim 22 (depends on 18)

The composition of claim 18, wherein the cell surface antigen is the CDIM epitope.

### Claim 23 (depends on 17)

The composition of claim 17, wherein the antibody is a VH4-34 antibody.

### Claim 24 (depends on 18)

The composition of claim 18, wherein the crosslinking agent is an anti-kappa agent, anti-lambda agent, or an anti-VH4-34 antibody.

### Claim 25

A composition for inducing cell membrane wounding in B cells, comprising a polyvalent VH4-34 antibody that binds to a cell surface antigen on the surface of the B cell.

### Claim 26 (depends on 25)

The composition of claim 25, further comprising a crosslinking agent that crosslinks the VH4-34 antibody bound to the cell surface antigen on the surface of the B cell.

### Claim 27 (depends on 26)

The composition of claim 26, wherein the crosslinking agent that crosslinks the VH4-34 antibody is an anti-VH4-34 antibody.

### Claim 28

A pharmaceutical composition for treating a mammal suffering from a condition characterized by hyperproliferation of cells, said pharmaceutical composition comprising a polyvalent agent that binds to a highly expressed cell surface antigen present on the surface of a cell, wherein said polyvalent agent induces cell membrane wounding.

### Claim 29 (depends on 28)

The pharmaceutical composition of claim 28, further comprising a cytotoxic agent.

### Claim 30 (depends on 28)

The pharmaceutical composition of claim 28, wherein the hyperproliferation of cells is a hyperproliferation of B cells.

### Claim 31 (depends on 30)

The pharmaceutical composition of claim 30, wherein the condition characterized by a hyperproliferation of B cells is lymphoid cancer, viral infection, immunodeficiency, or autoimmune disease.

### Claim 32 (depends on 31)

The pharmaceutical composition of claim 31, wherein said viral infection is human immunodeficiency virus or mononucleosis.

### Claim 33 (depends on 31)

The pharmaceutical composition of claim 31, wherein said immunodeficiency is post-transplant lymphoproliferative disease, or immunodeficiency syndrome

### Claim 34 (depends on 29)

The pharmaceutical composition of claim 29, wherein the cytotoxic agent is a chemotherapeutic agent, a radioactive isotope, a cytotoxic antibody, an immunoconjugate, a ligand conjugate, an immunosuppressant, a cell growth regulator and/or inhibitor, a toxin, or mixtures thereof.

### Claim 35 (depends on 28)

The pharmaceutical composition of claim 28, further comprising a crosslinking agent providing crosslinking of the polyvalent agent.

### Claim 36

A composition for augmenting cell membrane wounding induced by a cell membrane wounding antibody, comprising a polyvalent antibody that binds to a highly expressed cell surface antigen, and crosslinking means that augments the cytotoxicity of the polyvalent antibody, wherein the crosslinking means augments the cytotoxicity of the polyvalent antibody relative to the cytotoxicity of the polyvalent antibody in the absence of the crosslinking means.

### Claim 37 (depends on 36)

The composition of claim 36, wherein the polyvalent antibody is an IgM.

### Claim 38 (depends on 36)

The composition of claim 36, wherein the crosslinking means is an anti-kappa, anti-lambda, anti-mu antibody or an antibody specific for an epitope expressed on the polyvalent antibody that crosslinks adjacent polyvalent antibodies bound to the highly expressed cell surface antigen on the surface of the cell.

### Claim 39

A pharmaceutical composition for treating a mammal suffering from a condition characterized by hyperproliferation of cells, comprising a polyvalent agent that binds to a highly expressed cell surface antigen present on the surface of a cell, wherein said polyvalent agent comprises a plurality of binding sites for the cell surface antigen on the surface of the cell.

### Claim 40 (depends on 39)

The composition of claim 39, wherein the plurality of binding sites is at least five.

### Claim 41 (depends on 39)

The composition of claim 39, wherein the plurality of binding sites is from about 5 to about 100.

### Claim 42 (depends on 39)

The composition of claim 39, wherein the plurality of binding sites is from about 15 to about 50.

### Claim 43

A method of treating a mammal suffering from a condition characterized by a hyperproliferation of cells, comprising administering a polyvalent agent that binds a highly expressed cell surface receptor on the surface of the hyperproliferating cells, wherein said polyvalent agent is administered in an amount effective to preferentially kill the hyperproliferating cells relative to normal cells.

### Claim 44 (depends on 43)

The method of claim 43, wherein the mammal is a human.

### Claim 45 (depends on 44)

The method of claim 44, wherein the mammal is a nonhuman mammal.

### Claim 46 (depends on 43)

The method of claim 43, wherein the hyperproliferating cells are cancer cells.

### Claim 47 (depends on 46)

The method of claim 46, wherein the hyperproliferating cells are stimulated into a hyperproliferating condition by growth factors, cytokines, or viral infection.

### Claim 48 (depends on 43)

The method of claim 43, wherein the polyvalent agent is a cell membrane wounding antibody.

### Claim 49 (depends on 46)

The method of claim 46, wherein the viability of cancer cells can be reduced by an amount that is at least ten percent greater than the viability of normal cells.

### Claim 50

A method of killing a cancer cell, comprising contacting a cancer cell with a cytotoxic amount of a cell membrane wounding antibody that binds to a highly-expressed cell surface antigen on the surface of the cancer cell and induces cell membrane wounding in the cancer cell.

### Claim 51 (depends on 50)

The method of claim 50, wherein the cell membrane wounding antibody is administered in an amount effective to preferentially kill cancer cells, but not to kill normal cells.

### Claim 52 (depends on 50)

The method of claim 50, further comprising administering a cytotoxic agent in combination with the cell membrane wounding antibody.

### Claim 53 (depends on 52)

The method of claim 52, wherein the cytotoxic agent is a chemotherapeutic agent, a radioactive isotope, a cytotoxic antibody, an immunoconjugate, a ligand conjugate, an immunosuppressant, a cell growth regulator and/or inhibitor, a toxin, or mixtures thereof.

### Claim 54 (depends on 50)

The method of claim 50, further comprising administering a crosslinking agent providing crosslinking of the cell membrane wounding antibody that binds to a highly expressed cell surface antigen on the surface of the cancer cell.

### Claim 55 (depends on 54)

The method of claim 54, wherein the crosslinking agent is an antibody.

### Claim 56 (depends on 50)

The method of claim 50, wherein the cancer cell is a neoplastic B cell.

### Claim 57 (depends on 50)

The method of claim 50, wherein said cell membrane wounding antibody is a VH4-34 antibody.

### Claim 58 (depends on 55)

The method of claim 55, wherein the antibody is an anti-VH4-34 antibody.

### Claim 59

A method for inducing cell membrane wounding in a lymphoid cell in a human patient, comprising contacting a cell with a polyvalent agent that binds to a highly expressed cell surface antigen present on the surface of the lymphoid cell.

### Claim 60 (depends on 59)

The method of claim 59, wherein the polyvalent agent is an antibody.

### Claim 61 (depends on 59)

The method of claim 59, wherein the lymphoid cell is a B cell expressing the CDIM epitope.

### Claim 62 (depends on 59)

The method of claim 59, wherein the antibody is administered to the patient in an amount effective to preferentially wound hyperproliferating B cells relative to normal B cells.

### Claim 63 (depends on 59)

The method of claim 59, wherein the antibody is administered to the patient in an amount effective to wound hyperproliferating B cells but not effective to kill the hyperproliferating B cells.

### Claim 64 (depends on 62)

The method of claim 62, wherein the method comprises (1) sampling the blood of a patient in need of treatment to determine the number of hyperproliferating B cells in the blood of the patient, (2) determining the susceptibility of the hyperproliferating B cells and normal B cells to wounding by the antibody, and (3) administering an amount of the antibody to the patient sufficient to preferentially wound and/or kill hyperproliferating B cells in the patient.

### Claim 65 (depends on 64)

The method of claim 64, further comprising titrating in additional amounts of antibody to the patient to achieve a desired amount of cell wounding and/or killing.

### Claim 66 (depends on 63)

The method of claim 63, wherein the method comprises (1) sampling the blood of a patient in need of treatment to determine the number of hyperproliferating B cells in the blood of the patient, (2) determining the susceptibility of the hyperproliferating B cells to wounding by the antibody, and (3) administering an amount of the antibody to the patient sufficient to wound the hyperproliferating B cells in the patient.

### Claim 67 (depends on 59)

The method of claim 59, further comprising administering an effective amount of a cytotoxic agent to the patient.

### Claim 68

A method for inducing cell membrane wounding, comprising contacting a cell with a polyvalent agent that binds to a highly expressed cell surface antigen on the surface of the cell.

### Claim 69 (depends on 68)

The method of claim 68, further comprising contacting the cell with a crosslinking agent that augments the cytotoxicity of the polyvalent agent relative to the cytotoxicity of the polyvalent agent in the absence of the crosslinking agent.

### Claim 70 (depends on 69)

The method of claim 69, wherein the polyvalent agent is an antibody, and the crosslinking agent is an antibody that binds the antibody, providing crosslinking of the antibody bound to the surface of the cell.

### Claim 71 (depends on 68)

The method of claim 68, wherein the cell is a B cell and the antibody is an anti-CDIM antibody.

### Claim 72 (depends on 68)

The method of claim 68, wherein the anti-CDIM antibody is an IgM.

### Claim 73 (depends on 72)

The method of claim 72, further comprising a crosslinking agent that binds to the anti-CDIM antibody.

### Claim 74 (depends on 73)

The method of claim 73, wherein the crosslinking agent that binds to the anti-CDIM antibody is an anti-kappa or anti-lambda antibody or an anti-VH4-34 antibody.

### Claim 75

A method for permeabilizing a cell, comprising contacting a cell with a polyvalent agent that binds to a highly expressed cell surface antigen present on the surface of the cell.

### Claim 76

A method of treating a human patient suffering from a condition characterized by a hyperproliferation of B cells, comprising contacting said B cells with (1) a cytotoxic amount of an antibody having specific binding for CDIM epitopes on a B cell, and (2) a crosslinking agent that crosslinks the antibody having specific binding for CDIM epitopes on a B cell.

### Claim 77 (depends on 76)

The method of claim 76, further comprising contacting said B cells with a cytotoxic agent.

### Claim 78 (depends on 76)

The method of claim 76, wherein the condition characterized by a hyperproliferation of B cells is lymphoid cancer, viral infection, immunodeficiency, or autoimmune disease.

### Claim 79 (depends on 78)

The method of claim 78, wherein said viral infection is caused by HIV, EBV or HPV.

### Claim 80 (depends on 78)

The method of claim 78, wherein said immunodeficiency is post-transplant lymphoproliferative disease, or immunodeficiency syndrome

### Claim 81

A method of purging the bone marrow of malignant B cells from a patient in need thereof is provided, comprising contacting the bone marrow cells with an antibody having specific binding for a CDIM epitope on the surface of the B cells, and further comprising contacting the B cells with a crosslinking agent that crosslinks the antibody bound to the CDIM epitope on the surface of the B cells, thereby providing an enhanced cytotoxicity for the anti-CDIM antibody toward the malignant B cells.

### Claim 82 (depends on 81)

The method of claim 81, further comprising contacting the cells with a cytotoxic agent to further purge the bone marrow of malignant B cells.

### Claim 83

A kit for determining the dose threshold to a polyvalent agent that induces cell membrane wounding in a mammal, comprising a sufficient amount of a polyvalent agent that binds to a highly expressed cell surface antigen to perform binding assays.

### Claim 84

A kit for determining the dose threshold to a cell membrane wounding antibody in a mammal, comprising a sufficient amount of a cell wounding antibody that binds to a highly expressed cell surface antigen to perform binding assays, a crosslinking agent, or a cytotoxic agent, or combinations thereof.
